Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106486737> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2106486737 endingPage "73" @default.
- W2106486737 startingPage "65" @default.
- W2106486737 abstract "This review describes a long-standing experience of screening for interferon (IFN) inducers in Russia. IFN inducers represent a special group of potential antiviral compounds. The main requirements for them are (1) high IFN-inducing activity, (2) absence of side effects, (3) wide spectrum of antimicrobial activity, (4) broad therapeutic security and, (5) good solubility in water and biologic liquids. IFN inducers stimulate IFN production in different cells and organs, and that determines the strategy for their application. Amixin (OOO Lancepharm, Moscow, Russia) induces IFN-alpha/beta production mostly in T cells. Cycloferon (NTFF Polysan, St. Petersburg, Russia) stimulates B cells and macrophages to produce almost pure IFN-alpha. Double-stranded RNA (dsRNA) and polyphenols of natural origin stimulate IFN production in different populations of immunocytes. Only polymers, such as Larifan (Riga, Latvia), Kagocel (NIARnedicplus, Moscow, Russia), and Ragosin (N.F. Gamaleya Institute, Moscow, Russia), induce IFN synthesis in muscles, so they may be effective against rabies. Cycloferon, Larifan, and Kagocel, which induce IFN formation in lungs, may be effective against influenza and rhinoviral infections. Cycloferon and Larifan stimulate IFN production in liver and spleen and may be effective against hepatitis B. Oral compounds (Amixin, Kagocel) that stimulate IFN production in intestines may be effective against hepatitis A and enteroviral infections. Low molecular weight inducers (Amixin, Cycloferon, Kagocel) that penetrate the blood-brain barrier may be active against viral encephalitis. At present, clinical trials of IFN inducers are limited, but in the near future, IFN inducers may be used against very different infections and conditions." @default.
- W2106486737 created "2016-06-24" @default.
- W2106486737 creator A5010727371 @default.
- W2106486737 creator A5037224697 @default.
- W2106486737 creator A5051106296 @default.
- W2106486737 creator A5070972553 @default.
- W2106486737 date "2001-02-01" @default.
- W2106486737 modified "2023-09-27" @default.
- W2106486737 title "Russian Experience in Screening, Analysis, and Clinical Application of Novel Interferon Inducers" @default.
- W2106486737 cites W2006772331 @default.
- W2106486737 cites W2030624076 @default.
- W2106486737 cites W2064405210 @default.
- W2106486737 cites W2111253548 @default.
- W2106486737 cites W2142992472 @default.
- W2106486737 cites W2172262597 @default.
- W2106486737 doi "https://doi.org/10.1089/107999001750069926" @default.
- W2106486737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11244570" @default.
- W2106486737 hasPublicationYear "2001" @default.
- W2106486737 type Work @default.
- W2106486737 sameAs 2106486737 @default.
- W2106486737 citedByCount "13" @default.
- W2106486737 countsByYear W21064867372012 @default.
- W2106486737 countsByYear W21064867372013 @default.
- W2106486737 countsByYear W21064867372014 @default.
- W2106486737 countsByYear W21064867372016 @default.
- W2106486737 countsByYear W21064867372020 @default.
- W2106486737 countsByYear W21064867372023 @default.
- W2106486737 crossrefType "journal-article" @default.
- W2106486737 hasAuthorship W2106486737A5010727371 @default.
- W2106486737 hasAuthorship W2106486737A5037224697 @default.
- W2106486737 hasAuthorship W2106486737A5051106296 @default.
- W2106486737 hasAuthorship W2106486737A5070972553 @default.
- W2106486737 hasConcept C104317684 @default.
- W2106486737 hasConcept C159047783 @default.
- W2106486737 hasConcept C203014093 @default.
- W2106486737 hasConcept C2225953 @default.
- W2106486737 hasConcept C2776178377 @default.
- W2106486737 hasConcept C2909179924 @default.
- W2106486737 hasConcept C55493867 @default.
- W2106486737 hasConcept C71924100 @default.
- W2106486737 hasConcept C86803240 @default.
- W2106486737 hasConceptScore W2106486737C104317684 @default.
- W2106486737 hasConceptScore W2106486737C159047783 @default.
- W2106486737 hasConceptScore W2106486737C203014093 @default.
- W2106486737 hasConceptScore W2106486737C2225953 @default.
- W2106486737 hasConceptScore W2106486737C2776178377 @default.
- W2106486737 hasConceptScore W2106486737C2909179924 @default.
- W2106486737 hasConceptScore W2106486737C55493867 @default.
- W2106486737 hasConceptScore W2106486737C71924100 @default.
- W2106486737 hasConceptScore W2106486737C86803240 @default.
- W2106486737 hasIssue "2" @default.
- W2106486737 hasLocation W21064867371 @default.
- W2106486737 hasLocation W21064867372 @default.
- W2106486737 hasOpenAccess W2106486737 @default.
- W2106486737 hasPrimaryLocation W21064867371 @default.
- W2106486737 hasRelatedWork W1867220640 @default.
- W2106486737 hasRelatedWork W2020025751 @default.
- W2106486737 hasRelatedWork W2020810119 @default.
- W2106486737 hasRelatedWork W2075090863 @default.
- W2106486737 hasRelatedWork W2132748059 @default.
- W2106486737 hasRelatedWork W2406504617 @default.
- W2106486737 hasRelatedWork W2411762492 @default.
- W2106486737 hasRelatedWork W2415213224 @default.
- W2106486737 hasRelatedWork W4237867423 @default.
- W2106486737 hasRelatedWork W4250153761 @default.
- W2106486737 hasVolume "21" @default.
- W2106486737 isParatext "false" @default.
- W2106486737 isRetracted "false" @default.
- W2106486737 magId "2106486737" @default.
- W2106486737 workType "article" @default.